Peter DeMarco Biography, Age, Height, Wife, Net Worth and Family

He had a research laboratory and a medical practice in Pine Hill, New Jersey. He treated patients with procaine polyvinylpyrrolidone (PVP), but his medical license was suspended in New Jersey and Pennsylvania for using unapproved therapies after an experimental permit for PVP was withdrawn. The Federal agency (which?) also said the drug might cause cancer. This was a common misconception in the 1970s (citation needed). Later research revealed procaine may anti-cancer effects in human cancer cells.(More citations needed)

Peter Thomas DeMarco (March 6, 1932 – October 26, 2005) was an American physician who graduated from Albright College in Pennsylvania and achieved his doctor of medicine degree in 1957 from Hahnemann Medical College of Philadelphia, Pennsylvania.

Pharmaceutical company Johnson & Johnson’s Ortho Research Laboratory wrote that case histories of his therapy, “were quite remarkable and your concepts most intriguing” and ICN Pharmaceuticals replied, “The results you have obtained with this drug in the treatment of gangrene have been most spectacular”, but DeMarco was never able to commercialize the therapy beyond his own medical practice. Swiss pharmaceutical company Debiopharm S.A. replied, “Drug induced cell regeneration appears to be a revolutionary new form of treatment which is bound to be perceived as highly controversial by several regulatory agencies. We are not in a position to take the considerable time and risk involved in convincing the bureaucrats.” Thus although intrigued, the pharmaceutical companies never showed a serious interest in developing his product. Regenerative medicine was a new field at the time and DeMarco likened the companies’ antipathy of his discovery to the history of penicillin; although discovered in 1928, penicillin was not mass-produced until 1941 when production became a top priority World War II project to reduce the infection casualty rate.